Potential role of targeted therapies in the treatment of triple-negative breast cancer
MetadataShow full item record
Breast cancer is the most common cancer type that affects women and is the major cause of morbidity and mortality. Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype and accounts for 10–20% of all breast cancer cases. TNBC is commonly characterized by the absence of estrogen, progesterone, and the Her2/neu receptor and is usually diagnosed by immunohistochemistry. Mutations in the BRCA1 gene, as well as overexpression of oncogenic kinases, such as human epidermal growth factor receptor 2, vascular endothelial growth factor-A, insulin-like growth factor-1 (IGF-1)/IGF-1 receptor, and transforming growth factor-β1, have been found to be correlated with a higher risk of metastasis and poor overall survival in TNBC patients. The current review briefly discusses the various treatment options including chemotherapeutics and targeted therapies that are available currently for the therapy of TNBC patients and highlights their comparative benefits and disadvantages for clinical application.
Showing items related by title, author, creator and subject.
Datta, A.; Loo, S.; Huang, B.; Wong, L.; Tan, S.; Tan, T.; Lee, S.; Thiery, J.; Lim, Y.; Yong, W.; Lam, Y.; Kumar, Alan Prem; Yap, C. (2014)Triple-negative breast cancer (TNBC) is characterized by unique aggressive behavior and lack of targeted therapies. Among the various molecular subtypes of breast cancer, it was observed that TNBCs express elevated levels ...
Wang, C.; Kar, S.; Lai, X.; Cai, W.; Arfuso, Frank; Sethi, G.; Lobie, P.; Goh, B.; Lim, L.; Hartman, M.; Chan, C.; Lee, S.; Tan, S.; Kumar, A. (2018)While tremendous improvement has been made for the treatment of breast cancers, the treatment of triple negative breast cancer (TNBC) still remains a challenge due to its aggressive characteristics and limited treatment ...
PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast CancersChen, L.; Yuan, Y.; Kar, S.; Kanchi, M.; Arora, S.; Kim, J.; Koh, P.; Yousef, E.; Samy, R.; Shanmugam, M.; Tan, T.; Shin, S.; Arfuso, Frank; Shen, H.; Yang, H.; Goh, B.; Park, J.; Gaboury, L.; Lobie, P.; Sethi, G.; Lim, L.; Kumar, A. (2017)Metastatic breast cancer is still incurable so far; new specifically targeted and more effective therapies for triple-negative breast cancer (TNBC) are required in the clinic. In this study, our clinical data have established ...